The Elliot Lewis Center shares recent and relevant multiple sclerosis news articles and current events on this page. Please check back frequently for updated information.
April 10, 2017 – WCVB at The Elliot Lewis Center
Until now, people with a certain type of Multiple Sclerosis had no drugs available to slow the symptoms. A local health instructor is the first patient to receive the new drug called Ocrevus.
FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) For Relapsing and Primary Progressive Forms of Multiple Sclerosis
March 28, 2017 – Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. The majority of people with MS have a relapsing form or primary progressive MS at diagnosis.
The FDA’s approval of OCREVUS is the beginning of a new era for the MS community and represents a significant scientific advance with this first-in-class B cell targeted therapy,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “Until now, no FDA-approved treatment has been available to the primary progressive MS community, and some people with relapsing forms of MS continue to experience disease activity and disability progression despite available therapies. We believe OCREVUS, given every six months, has the potential to change the disease course for people with MS, and we are committed to helping those who can benefit gain access to our medicine.”
FDA Extends Its Review of Ocrelizumab as a Possible Therapy for Primary Progressive and Relapsing MS
December 20, 2016 – The U.S. Food and Drug Administration has extended its review of an application to approve ocrelizumab (Ocrevus,™ Genentech, a member of the Roche Group) for use in the treatment of primary progressive MS and relapsing forms of MS. Originally, a decision from the agency was expected by December 28, 2016. A decision about the approval is now expected by March 28, 2017.
A press release from Genentech, a member of the Roche Group, states that the extension will permit the FDA more time to review additional data submitted regarding the commercial manufacturing process for ocrelizumab. In addition, the company states that the extension is not related to the drug’s safety or efficacy.
MS Trial Alert: Investigators Recruiting for Study of Ocrelizumab in People with Relapsing-Remitting MS Who Have Not Responded to Other Therapies
December 14, 2016 – Investigators throughout the United States and Canada are recruiting for a study of intravenous ocrelizumab (Genentech, Inc.) in people with relapsing-remitting MS who have not responded to other disease-modifying therapies.
Participants in this study should be ages 18 to 55, with a diagnosis of relapsing-remitting MS. Participants have been treated with two or fewer disease-modifying therapies, each for six months or more. The most recent therapy was discontinued due to lack of effectiveness. For more details on enrollment, please contact our research team.
FDA approves Zinbryta to treat multiple sclerosis
May 27, 2016 – The U.S. Food and Drug Administration today approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a long-acting injection that is self- administered by the patient monthly.
“Zinbryta provides an additional choice to patients who may require a new option for treatment,” said Billy Dunn, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research.
Hacking for those with disabilities
MIT undergraduate and graduate students work in teams at the Assistive Technologies Hackathon (ATHack 2015) to create a prototype improving an aspect in the daily routine of their client, a person living with a disability.
MIT is currently seeking clients for the 2016 event. Clients should have a problem in mind: anything from something you are unable to do, an activity you would like to make easier or a passion you are unable to pursue. Teams of students, comprised of mechanical engineers electrical engineers, and computer scientists, will be matched with clients to try to develop a solution that addresses the need. The program is a 2-day event at MIT in Cambridge, MA on February 8th and February 27th. If you are interested in being part of the 2016 event, please email Marissa Hone at The Elliot Lewis Center at firstname.lastname@example.org Our center will be sending appropriate applications to MIT for further review.
High Doses of Biotin in Chronic Progressive Multiple Sclerosis: A Pilot Study
Biotin, a vitamin supplement, may provide benefits for patients with progressive forms of MS. Preliminary data appears promising, but it is too early to draw any conclusions. Listen to the podcast, where Dr. Joshua Katz and Dr. Ellen Lathi discuss this interesting topic.
Grey Matters Episode 3: Biotin
Positive Results Announced from Two Phase III Clinical Trials of Ocrelizumab in Relapsing MS
June 30, 2015 – Genentech announced that the experimental monoclonal antibody ocrelizumab significantly reduced relapse rates after two years compared to the established MS treatment, Rebif® (interferon beta-1a, EMD Serono and Pfizer) in two phase III studies. Ocrelizumab is administered by intravenous infusion every 6 months. The studies, known as OPERA I and OPERA II, included a total of 1,656 people with relapsing MS (people with relapsing-remitting MS and those with secondary-progressive MS who were experiencing relapses). Results of an ongoing trial in Primary Progressive MS expected later in 2015.